The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 7, 2004, Pages 1709-1712

  Tandon, Manish ^a   O'Donnell, Mary Margaret ^a   Porte, Alex ^a   Vensel, David ^a   Yang, Donglai ^a   Palma, Rocio ^a   Beresford, Alan ^a   Ashwell, Mark A ^a  

^a ARQULE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; PIPERAZINE DERIVATIVE; SEROTONIN;

ARTICLE; CHEMICAL MODIFICATION; DRUG BINDING; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME STABILITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HUMANS; LIGANDS; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGENTS;

EID: 1542404604     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.01.045     Document Type: Article

References (17)

1. Rendic S. Drug Metab. Rev. 34:2002;83.
2. Wu Y.-H., Rayburn J.W., Allen L.E., Ferguson H.C., Kissel J.W. J. Med. Chem. 15:1972;477.
3. (b) Tunicliff, G.; Eison, A. S.; Taylor, D. P., Eds. In Buspirone: Mechanism and Clinical Aspects; Academic Press Inc, 1991.
4. Jones J.P., Mysinger M., Korzekwa K.R. Drug Metab. Dispos. 30:2002;7.
5. Korzekwa K.R., Jones J.P., Gillette J.R. J. Am. Chem. Soc. 112:1990;7042.
6. Jajoo H.K., Mayol R.F., LaBudde J.A., Blair I.A. Drug Metab. Dispos. 17:1989;634.
7. Jajoo H.K., Mayol R.F., LaBudde J.A., Blair I.A. Drug Metab. Dispos. 17:1989;625.
8. Sakr A., Andheria M. J. Clin. Pharmacol. 41:2001;886.
9. Lopez-Rodriguez M.L., Ayala D., Benhamu B., Morcillo M.J., Viso A. Curr. Med. Chem. 9:2002;443.
10. PhysChem Batch software, v6.13; http://www.acdlabs.com/products/phys_chem
11. Lopez-Rodriguez M.L., Rosado M.L., Benhamu B., Morcillo M.J., Fernandez E., Schaper K.-J. J. Med. Chem. 40:1997;1648.
12. Glennon R.A., Naiman N.A., Pierson M.E., Titeler M., Lyon R.A., Herndon J.L., Misenheimer B. Drug Dev. Res. 16:1989;335.
13. All new compounds were prepared in a parallel chemistry fashion, purified by RP-HPLC and characterized by HPLC-MS.
14. Ishizumi K., Kojima A., Antoku F., Ikutaro S., Yoshigi M. Chem. Pharm. Bull. 43:1995;2139.
15. For a detailed description of the assay methodology see: Saraswat L., Caserta K.A., Laws K., Wei D., Jones S.J., Adedoyin A. J. Biomolecular Screening. 8:2003;544.
16. 1A binding: Kahl S.D., Hubbard F.R., Sittampalam G., Zock J.M. J. Biomolecular Screening. 2:1997;33.
17. Kalgutkar A.S., Zhou S., Fahmi O.A., Taylor T.J. Drug Metab. Dispos. 31:2003;596.